A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Board Certified in Endocrinology, Diabetes, and Metabolism and Internal Medicine, Dr. Caveney leads IQVIA’s Obesity, ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

Full data will be reported soon from the SURMOUNT-5 trial on comparison of weight loss with tirzepatide vs semaglutide 2.4 mg, for which, top-line results suggest superiority of tirzepatide.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney ... the FLOW trial of semaglutide ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

But the popular injection is seeing new competition with Mounjaro, and now a daily pill which could help patients lose 16 ...

It has also been shown to reduce kidney ... neither semaglutide nor tirzepatide are very good at penetrating the central nervous system. The investigator-led phase 2 LixiPark trial of lixisenatide ...

Breaking bread is a powerful act of connection and shared moments, transcending barriers and bridging gaps. As we break bread we promote friendship, trust, and a sense of belonging.